Journal
CELL
Volume 162, Issue 3, Pages 516-526Publisher
CELL PRESS
DOI: 10.1016/j.cell.2015.07.003
Keywords
-
Categories
Funding
- CHDI Foundation
- National Institutes of Health (USA) [X01HG006074, U01NS082079, R01NS091161, R01HG002449, P50NS016367]
- Medical Research Council (UK) [G0801418, MR/L010305/1]
- Auspex Pharmaceuticals
- Prana Biotechnology Ltd
- Medical Research Council [MR/L012936/1, MR/L010305/1, MR/L023784/2, G0801418] Funding Source: researchfish
- MRC [G0801418, MR/L023784/2] Funding Source: UKRI
Ask authors/readers for more resources
As a Mendelian neurodegenerative disorder, the genetic risk of Huntington's disease (HD) is conferred entirely by an HTT CAG repeat expansion whose length is the primary determinant of the rate of pathogenesis leading to disease onset. To investigate the pathogenic process that precedes disease, we used genome-wide association (GWA) analysis to identify loci harboring genetic variations that alter the age at neurological onset of HD. A chromosome 15 locus displays two independent effects that accelerate or delay onset by 6.1 years and 1.4 years, respectively, whereas a chromosome 8 locus hastens onset by 1.6 years. Association at MLH1 and pathway analysis of the full GWA results support a role for DNA handling and repair mechanisms in altering the course of HD. Our findings demonstrate that HD disease modification in humans occurs in nature and offer a genetic route to identifying in-human validated therapeutic targets in this and other Mendelian disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available